Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last?Zacks Investment Research • 10/12/22
Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?Zacks Investment Research • 09/16/22
Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/01/22
Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision PathwayGlobeNewsWire • 08/26/22
Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 EarningsSeeking Alpha • 08/09/22
Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/02/22
Esperion Reports Second Quarter 2022 Financial Results and Provides Company UpdateGlobeNewsWire • 08/02/22
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle ManagementGlobeNewsWire • 07/25/22
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Esperion Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 06/15/22
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any StatinGlobeNewsWire • 06/03/22
Esperion Therapeutics (ESPR) Down 15.1% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/02/22
Esperion Announces the Appointment of J. Martin Carroll to its Board of DirectorsGlobeNewsWire • 06/01/22
Esperion to Participate in Upcoming H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/17/22
Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
Esperion Reports First Quarter 2022 Financial Results and Provides Company UpdateGlobeNewsWire • 05/03/22
Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare ConferenceGlobeNewsWire • 04/29/22
Esperion Announces the Appointment of Stephen Rocamboli to its Board of DirectorsGlobeNewsWire • 04/28/22
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/26/22